MADD, a splice variant of IG20 (insulinoma-glucagonoma 20) overexpressed in cancer cells [29], is crucial for RAS/MEK/ERK activation by facilitating recruitment of Grb2 to the receptor-mediated signaling complex [30]. Here, MAP2K7 is linked to cancer.